Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Diroximel Fumarate · Vumerity, BIIB-098

Small molecule · Agonist of NFE2L2 (Nrf2) (NFE2L2) · developed by Biogen

Approved FDA, Oct 2019

BIIB Developer

1 Registered trials

What is Diroximel Fumarate?

Diroximel fumarate is a small-molecule prodrug that is metabolized to monomethyl fumarate (MMF). MMF activates the Nrf2 pathway, which regulates cellular responses to oxidative stress, and acts as a nicotinic acid receptor agonist.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Vumerity, BIIB-098, ALKS-8700, VUMERITY
Drug type: Small molecule
Targets: NFE2L2 (Nrf2) (NFE2L2), nicotinic acid receptor (secondary target)
Mechanism: Agonist of NFE2L2 (Nrf2) (NFE2L2)
Pathways: oxidative stress response
Therapy area: Neurology
Developer: Biogen (BIIB)
FDA status: Approved as Vumerity (October 29, 2019), NDA211855 · FDA label
UNII: K0N0Z40J3W

✅ FDA-approved uses

Relapsing forms of multiple sclerosis

From the indications section of the FDA label (version of May 29, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05688436	N/A	Multiple Sclerosis	Active not recruiting	BIIB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple Sclerosis

Other drugs acting on NFE2L2

Dimethyl Fumarate FDA approved Omaveloxolone FDA approved

More from Biogen

Dimethyl Fumarate FDA approved Interferon Beta-1A FDA approved Natalizumab FDA approved Nusinersen FDA approved Omaveloxolone FDA approved Tofersen FDA approved Zuranolone FDA approved BIIB115 Phase 1 BIIB122 Phase 3 BIIB144 Phase 1 BIIB147 Phase 1/2 Diranersen Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BIIB page.

Follow BIIB, the company behind Diroximel Fumarate

See BIIB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BIIB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z